BACKGROUND: The role of systemic chemotherapy (SC) in conjunction with cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in appendiceal mucinous carcinoma peritonei (MCP) is unknown. METHODS: A retrospective review (1999-2011) of MCP patients who had undergone CS/HIPEC with or without perioperative SC. RESULTS: Twenty-two low-grade MCP patients treated with CS/HIPEC and SC were matched to patients who received CS/HIPEC alone. Median overall survival (OS) was 107 months for patients treated with perioperative SC compared to 72 without (P = 0.46). CS/HIPEC was performed on 109 patients with high-grade MCP: 70 were treated with perioperative SC, while 39 were not. Median OS (22.1 vs. 19.6 months, P = 0.74) and progression-free survival (PFS) (10.9 vs. 7.0 months, P = 0.47) were similar in patients treated with SC compared to CS/HIPEC alone. Progression while on pre-operative SC was seen in eight patients (17%), while four (8%) had a partial response. Treatment with post-operative SC was associated with longer PFS (13.6 months) compared to pre-operative SC (6.8 months, P < 0.01) and CS/HIPEC alone (7.0 months, P = 0.03). CONCLUSIONS: Post-operative SC appears to improve PFS in patients with high-grade appendiceal MCP treated with CS/HIPEC. In contrast, there is no evidence to support the routine use of perioperative SC in low-grade disease.
BACKGROUND: The role of systemic chemotherapy (SC) in conjunction with cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in appendiceal mucinous carcinoma peritonei (MCP) is unknown. METHODS: A retrospective review (1999-2011) of MCP patients who had undergone CS/HIPEC with or without perioperative SC. RESULTS: Twenty-two low-grade MCP patients treated with CS/HIPEC and SC were matched to patients who received CS/HIPEC alone. Median overall survival (OS) was 107 months for patients treated with perioperative SC compared to 72 without (P = 0.46). CS/HIPEC was performed on 109 patients with high-grade MCP: 70 were treated with perioperative SC, while 39 were not. Median OS (22.1 vs. 19.6 months, P = 0.74) and progression-free survival (PFS) (10.9 vs. 7.0 months, P = 0.47) were similar in patients treated with SC compared to CS/HIPEC alone. Progression while on pre-operative SC was seen in eight patients (17%), while four (8%) had a partial response. Treatment with post-operative SC was associated with longer PFS (13.6 months) compared to pre-operative SC (6.8 months, P < 0.01) and CS/HIPEC alone (7.0 months, P = 0.03). CONCLUSIONS: Post-operative SC appears to improve PFS in patients with high-grade appendiceal MCP treated with CS/HIPEC. In contrast, there is no evidence to support the routine use of perioperative SC in low-grade disease.
Authors: Edward A Levine; Dan G Blazer; Mickey K Kim; Perry Shen; John H Stewart; Cynthia Guy; David S Hsu Journal: J Am Coll Surg Date: 2012-02-17 Impact factor: 6.113
Authors: Dominique Elias; Olivier Glehen; Marc Pocard; François Quenet; Diane Goéré; Catherine Arvieux; Patrick Rat; François Gilly Journal: Ann Surg Date: 2010-05 Impact factor: 12.969
Authors: C H Lieu; L A Lambert; R A Wolff; C Eng; N Zhang; S Wen; S Rafeeq; M Taggart; K Fournier; R Royal; P Mansfield; M J Overman Journal: Ann Oncol Date: 2011-06-08 Impact factor: 32.976
Authors: Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger Journal: Am J Surg Pathol Date: 2006-05 Impact factor: 6.394
Authors: John H Stewart; Perry Shen; Gregory B Russell; Robert F Bradley; Jonathan C Hundley; Brian L Loggie; Kim R Geisinger; Edward A Levine Journal: Ann Surg Oncol Date: 2006-03-14 Impact factor: 5.344
Authors: Ryan B Morgan; Allie Yan; Ankit Dhiman; Ardaman Shergill; Blase Polite; Kiran K Turaga; Oliver S Eng Journal: J Gastrointest Surg Date: 2022-07-25 Impact factor: 3.267
Authors: Harveshp D Mogal; Edward A Levine; Greg Russell; Perry Shen; John H Stewart; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2015-08-20 Impact factor: 5.344
Authors: Kathleen A Cummins; Gregory B Russell; Konstantinos I Votanopoulos; Perry Shen; John H Stewart; Edward A Levine Journal: J Gastrointest Oncol Date: 2016-02
Authors: Edward A Levine; Konstantinos I Votanopoulos; Perry Shen; Greg Russell; Joyce Fenstermaker; Paul Mansfield; David Bartlett; John H Stewart Journal: J Am Coll Surg Date: 2018-01-10 Impact factor: 6.113
Authors: Ashok K Dilly; Brendon D Honick; Robin Frederick; Anuleka Elapavaluru; Sachin Velankar; Hima Makala; T Kevin Hitchens; Lesley M Foley; Jianxia Guo; Jan H Beumer; Lora Heather Rigatti; Yong J Lee; David L Bartlett; Haroon A Choudry Journal: Transl Res Date: 2020-10-22 Impact factor: 7.012
Authors: Steven D Forsythe; Richard A Erali; Shyama Sasikumar; Preston Laney; Ethan Shelkey; Ralph D'Agostino; Lance D Miller; Perry Shen; Edward A Levine; Shay Soker; Konstantinos I Votanopoulos Journal: Clin Cancer Res Date: 2021-07-01 Impact factor: 13.801